INMB icon

INmune Bio

4.40 USD
-0.02
0.45%
At close Dec 20, 4:00 PM EST
After hours
4.40
+0.00
0.00%
1 day
-0.45%
5 days
-7.17%
1 month
-3.51%
3 months
-15.71%
6 months
-42.86%
Year to date
-60.78%
1 year
-55.73%
5 years
-27.87%
10 years
-44.93%
 

About: INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.

Employees: 17

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

550% more call options, than puts

Call options by funds: $2M | Put options by funds: $308K

300% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 7

90% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 10

16% more funds holding

Funds holding: 56 [Q2] → 65 (+9) [Q3]

0.91% more ownership

Funds ownership: 23.23% [Q2] → 24.14% (+0.91%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

29% less capital invested

Capital invested by funds: $40.5M [Q2] → $28.8M (-$11.7M) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$18
309%
upside
Avg. target
$19
332%
upside
High target
$20
355%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Alliance Global Partners
James Molloy
0% 1-year accuracy
0 / 10 met price target
355%upside
$20
Buy
Initiated
21 Oct 2024
Raymond James
309%upside
$18
Outperform
Initiated
27 Sept 2024

Financial journalist opinion

Neutral
Business Wire
2 weeks ago
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower
HOUSTON & BOCA RATON, Fla.--(BUSINESS WIRE)--OmniScience and INmune Bio (NASDAQ: INMB) today announced a pioneering partnership to revolutionize operations for INmune Bio's global Phase 2 Alzheimer's disease (AD) clinical trial (the “AD02 trial”) using OmniScience's flagship product, Vivo, an industry-first, genAI-powered control tower designed specifically for centralizing and analyzing vast clinical data in real time. This solution represents an innovative approach to clinical research, deliv.
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower
Neutral
GlobeNewsWire
2 weeks ago
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower
Vivo Empowers Clinical Development Teams to Accelerate Decision-making and Analyses in Clinical Trials for Improved Outcomes HOUSTON and BOCA RATON, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- OmniScience and INmune Bio (NASDAQ: INMB) today announced a pioneering partnership to revolutionize operations for INmune Bio's global Phase 2 Alzheimer's disease (AD) clinical trial (the “AD02 trial”) using OmniScience's flagship product, Vivo, an industry-first, genAI-powered control tower designed specifically for centralizing and analyzing vast clinical data in real time.
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower
Neutral
Seeking Alpha
1 month ago
INmune Bio, Inc. (INMB) Q3 2024 Earnings Call Transcript
INmune Bio, Inc. (NASDAQ:INMB ) Q3 2024 Earnings Conference Call October 31, 2024 4:00 PM ET Company Participants David Moss - CFO Raymond Tesi - CEO & Co-Founder Christopher Barnum - Head of Neuroscience Mark Lowdell - Chief Scientific Officer Conference Call Participants Gary Nachman - Raymond James George Farmer - Scotiabank Joel Beatty - Baird Thomas Shrader - BTIG Operator Greetings, and welcome to the INmune Bio Third Quarter 2024 Earnings Call. As a reminder, this conference is being recorded.
INmune Bio, Inc. (INMB) Q3 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
1 month ago
INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update
BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2024 and provides a business update.
INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update
Neutral
GlobeNewsWire
1 month ago
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB
“Why EMACC is the Optimal Tool for Measuring Cognitive Change in Early Alzheimer's Trials” Webinar to be Held on November 7, 2024, at 1 PM ET.
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB
Neutral
GlobeNewsWire
1 month ago
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination
Data from Animal Model Study Demonstrate XPro™ converts m icroglia from a demyelinating cell to a remyelinating cell
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination
Neutral
GlobeNewsWire
1 month ago
INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 24, 2024 (GLOBE NEWSWIRE) --   INmune Bio Inc . (NASDAQ: INMB) (the “Company”),  a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer's Disease (AD), today announced that it will host a conference call on Thursday October 31, 2024, at 4:30pm EDT to discuss results for its quarter ended September 30, 2024 and to provide a corporate update.
INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024
Neutral
GlobeNewsWire
2 months ago
INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit
Boca Raton, Florida, Oct. 11, 2024 (GLOBE NEWSWIRE) --    INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer's Disease (AD), today announced that management will participate in the upcoming Maxim Healthcare Virtual Summit, to be held October 15-17, 2024.
INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit
Neutral
Seeking Alpha
2 months ago
INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal
INmune Bio's initial results from cohort 1 of the phase I/II CaRe PC trial, using INKmune for the treatment of patients with mCRPC released; Additional results from higher cohorts expected throughout 2025. It is said that the global metastatic castrate resistant prostate cancer market is projected to reach $20.70 billion by 2031. INMB completed enrollment of AD02 Phase 2 study, using XPro for patients with Alzheimer's Disease expected in Q3 of 2024, with clinical data expected 6 months after last patient recruited.
INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal
Neutral
GlobeNewsWire
2 months ago
INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort
BOCA RATON, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer (NK) cell therapy, INKmune™, in a Phase I/II trial (the “CaRe PC” trial) for men with metastatic Castration-Resistant Prostate Cancer (mCRPC). The Company is pleased to announce initial results from the first patient cohort in the trial.
INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort
Charts implemented using Lightweight Charts™